Ignite Creation Date:
2024-05-06 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 2:15 PM
Study NCT ID:
NCT05075538
Status:
TERMINATED
Last Update Posted:
2024-01-17
First Post:
2021-10-07
Brief Title:
COVID-19 Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
Sponsor:
Jules Bordet Institute
Organization:
Jules Bordet Institute
Study Overview
Official Title:
COVID-19 Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
Status:
TERMINATED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The population as defined by the inclusionexclusion criteria and the study logistics were leading to a poor recruitment over the past years
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
I-SPARC
Brief Summary:
This trial aims to measure the humoral and adaptive immune response in patients with cancer diagnosis undergoing mRNA vaccination against SARS-CoV-2 and assess its efficacy in preventing COVID-19
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2021-003710-39 | EUDRACT_NUMBER | None | None |